the dual (et and et) endothelin receptor antagonist bosentan was approved in 2001. sitaxentan (thelin) was approved for use in canada, australia, and the european union, but not in the united states. in 2010, pfizer withdrew thelin worldwide because of fatal liver complications. a similar drug, ambrisentan is marketed as letairis in the u.s. by gilead sciences.